Platform

Nutraceuticals

Cosmetics

Standards

Request a Sample Pack

Platform

Nutraceuticals

Cosmetics

Standards

Request a Sample Pack

Nativome by Botalys

KOREAN GINSENG

KOREAN GINSENG

Panax ginseng C.A. Meyer, root

Cold-pressed juice from an aseptically grown ginseng root. No heat, no solvent, no drying step. The complete native profile of the root, in the proportions the plant produced it.

Positioned for anti-aging, on the cellular longevity axis. The first preclinical data measured on this material are below.

Nativome Ginseng texture

What is it

PRESSED, NOT EXTRACTED

PRESSED, NOT EXTRACTED

The root is harvested from a sealed cleanroom and pressed within hours, without drying and without steaming. The juice is clarified by sterile filtration and standardized by HPLC on every batch. Most botanical actives are a fraction pulled out of the plant and rebuilt in a carrier. This one is the plant, stabilized for shelf life without propylene glycol.

The published literature on Panax ginseng was almost entirely built on dried, steamed or fermented root. Steaming converts the polar ginsenosides into deglycosylated forms and creates Maillard reaction products that fresh root does not contain. Nativome Ginseng is a different material from the one most of that literature describes.

Nativome

FORM

CLARIFIED JUICE

INCLUSION

1 TO 3%

PRESERVATIVES

NONE

ORIGIN

BELGIUM

WHAT IT DOES

WHAT IT DOES

CELLULAR LONGEVITY

CELLULAR LONGEVITY

SIRT1 gene expression increased in a dose-dependent manner in human dermal fibroblasts. Extracellular vesicles from Panax ginseng have been reported to improve senescent phenotypes in the same cell type.


MEASURED ON NATIVOME GINSENG

1 study on this material, in vitro · 3 supporting studies on ginseng compounds

BARRIER AND HYDRATION

BARRIER AND HYDRATION

Upregulation of aquaporin 3, filaggrin, loricrin and hyaluronic acid synthases. Shown for compounds isolated from fresh ginseng root, and benchmarked against retinol.

SCIENTIFIC EVIDENCE

STRONG

6 studies cited, in vitro and in vivo animal

COLLAGEN AND MATRIX

COLLAGEN AND MATRIX

Inhibition of MMP-1 and modulation of the dermal matrix through Smad signaling. Replicated across independent groups and multiple cell lines.

SCIENTIFIC EVIDENCE

STRONG

9 studies cited, in vitro and in vivo animal

STRONG, replicated by independent groups in more than one model. MODERATE, shown by a single group or in a single model. EMERGING, mechanistic signal only. MEASURED ON NATIVOME GINSENG, generated on the material sold under this name.

Nativome Ginseng bottle with a fresh Korean ginseng root

NATIVOME GINSENG: LONGEVITY, ACTIVATED

NATIVOME GINSENG: LONGEVITY, ACTIVATED

NATIVOME GINSENG: LONGEVITY, ACTIVATED

SIRT1, DOSE-DEPENDENT, IN THREE INDEPENDENT EXPERIMENTS

Nativome Ginseng increases SIRT1 gene expression in adult human dermal fibroblasts. The response follows the dose in every experiment, and the three experiments agree with each other to within four percent at the active dose.

SIRT1 is one of the best-characterized nodes of the cellular longevity axis in skin. This is the first evidence generated on this material, rather than on the wider literature that surrounds the plant.

SIRT1 relative expression in human dermal fibroblasts, dose dependent increase across three independent experiments.

Adult human dermal fibroblasts, primary culture. 24 h treatment, 1% FBS.

RT-qPCR, GAPDH normalization, 2^-ddCt. Three independent experiments.

Three concentrations tested, equivalent to 0.05, 0.1 and 0.2% of Nativome Ginseng in the culture medium. Relative SIRT1 expression 1.04, 1.11 and 1.27.

p < 0.01 at the active dose. Study PKDERM, 2026. Full report released to qualified laboratories.

IL-6 REDUCED UNDER INFLAMMATORY CHALLENGE

IL-6 REDUCED UNDER INFLAMMATORY CHALLENGE

Botalys ginseng root juice reduced IL-6 release in human keratinocytes under inflammatory challenge, at every concentration tested below 0.2%, by up to 46%. Four of five Botalys root materials reduced IL-6 in the same study. Confirmation on Nativome Ginseng is in progress.

IL-6 release in human keratinocytes under inflammatory challenge, reduced by Botalys ginseng root juice.

Human epidermal keratinocytes, PMA and calcium ionophore challenge. 24 h treatment.
IL-6 quantified by ELISA, normalized to cell viability. n = 3.
Study StratiCELL, 2024. Confirmation on Nativome Ginseng in progress.

MODE OF ACTION: FIVE COMPOUND FAMILIES, EIGHT MOLECULAR TARGETS

MODE OF ACTION: FIVE COMPOUND FAMILIES, EIGHT MOLECULAR TARGETS

MODE OF ACTION: FIVE COMPOUND FAMILIES, EIGHT MOLECULAR TARGETS

Saponins, polysaccharides, phenolic acids, phytosterols and peptides, and the skin pathways each family acts on.

COMPOUND FAMILIES

GINSENOSIDES

POLYSACCHARIDES

PHENOLIC ACIDS

PHYTOSTEROLS

PEPTIDES AND VESICLES

MOLECULAR TARGETS

MMP-1

From ginsenosides, polysaccharides, phenolic acids

→ FIRMNESS AND WRINKLES

COL1A1 / Smad

From ginsenosides, peptides and vesicles

→ FIRMNESS AND WRINKLES

NF-κB / COX-2

From ginsenosides, phenolic acids, phytosterols

→ REDNESS

Nrf2 / ROS

From phenolic acids

→ FIRMNESS AND WRINKLES · REDNESS

HAS 1/2/3

From ginsenosides, polysaccharides

→ HYDRATION

AQP3

From ginsenosides, polysaccharides

→ BARRIER INTEGRITY · HYDRATION

Filaggrin / loricrin

From polysaccharides

→ BARRIER INTEGRITY

Tyrosinase / MITF

From ginsenosides, phenolic acids

→ EVEN TONE

SKIN OUTCOMES

FIRMNESS AND WRINKLES

BARRIER INTEGRITY

HYDRATION

REDNESS

EVEN TONE

THE RECORD: CLAIMS AND SUPPORTING EVIDENCE

THE RECORD: CLAIMS AND SUPPORTING EVIDENCE

THE RECORD: CLAIMS AND SUPPORTING EVIDENCE

Evidence strength above reflects the published work on Panax ginseng root compounds, not on the Botalys ingredient itself. Studies conducted on Nativome Ginseng are reported separately and identified as such.

Human clinical work on ginseng is limited. A small number of studies with instrumental outcomes, twenty to twenty-three subjects, four to eight weeks, none of them on fresh root material. We publish this because a formulator will find it anyway.

FORMULATION

WORKING WITH IT

WORKING WITH IT

RECOMMENDED USE LEVELS

3% Hero SKU

Where the ingredient carries the claim.

2% Standard

Default inclusion across a range.

1% Floor

Formulation minimum, not an efficacy threshold.

The dose-response curve for this material is being established in preclinical study. Finished formula tolerance should be confirmed by the formulator.

TAKE IT INTO A FORMULA

TAKE IT INTO A FORMULA

Technical documentation and formulation samples are available to qualified laboratories.

REQUEST A SAMPLE

KOREAN GINSENG
────────

RHODIOLA ROSEA
────────

SOCIAL
────────

••••••
SUPPORTED BY EU
The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 859096.

DISCLAIMER
This website is intended to provide general information to industry experts and Health professionals and is not designed for the general public. Since BOTALYS active ingredients are being marketed in multiple countries around the world, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.

BOTALYS makes the sourcing of rare medicinal plants both possible & sustainable through biomimetic indoor farming, allowing its customers to harness the full potential of biodiversity - all while preserving it.

BOTALYS S.A.
Avenue des Artisans 8 box 6
7822 Ghislenghien, Belgium
TIN: BE 0834.134.177
+32 (0) 68 33 18 08

BOTALYS, Inc.
8205 Mescalero Dr
Austin, TX 78736, USA
+1 (512) 6472578
info@botalys.com

Copyright © BOTALYS SA. All rights reserved.

KOREAN GINSENG
────────

RHODIOLA ROSEA
────────

SOCIAL
────────

••••••
SUPPORTED BY EU
The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 859096.

DISCLAIMER
This website is intended to provide general information to industry experts and Health professionals and is not designed for the general public. Since BOTALYS active ingredients are being marketed in multiple countries around the world, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.

BOTALYS makes the sourcing of rare medicinal plants both possible & sustainable through biomimetic indoor farming, allowing its customers to harness the full potential of biodiversity - all while preserving it.

BOTALYS S.A.
Avenue des Artisans 8 box 6
7822 Ghislenghien, Belgium
TIN: BE 0834.134.177
+32 (0) 68 33 18 08

BOTALYS, Inc.
8205 Mescalero Dr
Austin, TX 78736, USA
+1 (512) 6472578
info@botalys.com

Copyright © BOTALYS SA. All rights reserved.